Abstract
Background Subunit vaccines are often poor immunogens compared to live-attenuated and whole-inactivated virus vaccines. One reason is the lack of costimulatory signals provided by various components of live-attenuated and wholeinactivated vaccines. Here we improved the immunogenicity of the HIV-1 envelope glycoproteins (Env) by direct fusion to a costimulatory molecule, CD40 ligand (CD40L), which we term 'cis-adjuvant'. The rationale was to target the antigen directly to dendritic cells (DC) and B cells, while at the same time activating these cells.
Highlights
Subunit vaccines are often poor immunogens compared to live-attenuated and whole-inactivated virus vaccines
After incubation with immature monocyte-derived dendritic cells (DC), the upregulation of DC maturation markers was monitored by FACS and the secretion of cytokines was analyzed by ELISA
Mice were immunized with plasmids encoding gp140 or gp140-CD40 ligand (CD40L) via intramuscular or dermal routes and the Envspecific antibody response was followed by ELISA
Summary
Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand. Address: 1Academic Medical Center, Amsterdam, Netherlands and 2Microbology and Immunology, Weill Medical College of Cornell University, New York, USA. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P81 doi:10.1186/1742-4690-6-S3-P81. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
